Clinical Trials
197 trialsA Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
ASPEN-09-03
ALX Oncology Inc.
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Blueprint Medicines Corporation
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
Amgen
MAPKeeper 301
Immuneering Corporation
DUAL-NK-PDAC
Beijing Biotech
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
SUNRAY-01
Eli Lilly and Company
OMNIRAY
Eli Lilly and Company
FORAGER-2
Eli Lilly and Company
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Gilead Sciences
HERMIA
Abscint NV/SA
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Ipsen
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Ipsen
IDeate-Prostate02
Merck Sharp & Dohme LLC
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Shenzhen Ionova Life Sciences Co., Ltd.
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
ASCEND
Crescent Biopharma, Inc.
A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
NEOK Bio, Inc.
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Nuvalent Inc.
NeoB-Cap1
Novartis
FRAmework-01
Eli Lilly and Company
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
AHEAD-MERIT
BioNTech SE
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
NEXUS-01
Eli Lilly and Company
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
BeOne Medicines
INDIGO
Boston Scientific Corporation
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
FORAGER-1
Eli Lilly and Company
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
VISTA-1
Riboscience, LLC.
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Keynote B59
GI Innovation, Inc.
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Exelixis
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Arsenal Biosciences, Inc.
OP-NEU-101
Onchilles Pharma Inc